Amgen Inc (AMGN NASDAQ) stock market data APIs
$354.1873
-0.3(-0.1%)
as of March 25, 2026
Try our APIs with
free plan!
Amgen Inc Financial Data Overview
Price chart is built with
Anychart
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Prev. Close
354.1873
Open
353.8828
High
360.9788
Low
353.8613
52 wk Range
253.4778-391.29
Market Cap
190 792 M
P/E Ratio
24.8721
Shares Outstanding
539 M
Revenue
36 751 M
EPS
5.29
Dividends (Yield)
0.0273
Beta
0.425
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Amgen Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc data using free add-ons & libraries
Get Amgen Inc Fundamental Data
Amgen Inc Fundamental data includes:
- Net Revenue: 36 751 M
- EBITDA: 16 617 M
- Earnings Per Share: 14
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-02
- EPS/Forecast: 4.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc News
New
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
SK pharmteco Inc. Innovations in Pharmaceutical Manufacturing: Continuous Manufacturing, Advanced Processing & Scalable Technologies on April 8th to feature top experts RANCHO CORDOVA, Calif., March...
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Amgen (AMGN) closed at $353.93 in the latest trading session, marking a +1.58% move from the prior day. This move outpaced the S&P 500's daily gain of 0.54%. At the same time, the Dow added 0.66%, and...
SCHD Annual Reconstitution: Here's What This Dividend ETF Looks Like Now
Every year in March, the Schwab U.S. Dividend Equity ETF(NYSEMKT: SCHD) reconstitutes and rebalances itself. This essentially means that it runs its strategic methodology from scratch and rebuilds its...
Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $375 and maintaine...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
